These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1719285)

  • 1. Evidence for medial-mass regression in the vascular wall of Dahl hypertensive rats by cicletanine treatment.
    Uehara Y; Numabe A; Kawabata Y; Nagata T; Iwai J; Matsuoka H; Yagi S; Takabatake Y; Sugimoto T
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):158-66. PubMed ID: 1719285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effects of cicletanine and renal protection in Dahl salt-sensitive rats.
    Uehara Y; Numabe A; Hirawa N; Kawabata Y; Iwai J; Ono H; Matsuoka H; Takabatake Y; Yagi S; Sugimoto T
    J Hypertens; 1991 Aug; 9(8):719-28. PubMed ID: 1655882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of endothelial cell function by chronic cicletanine treatment in Dahl salt-sensitive rats with salt-induced hypertension.
    Hirawa N; Uehara Y; Kawabata Y; Akie Y; Ichikawa A; Funahashi N; Goto A; Omata M
    Hypertens Res; 1996 Dec; 19(4):263-70. PubMed ID: 8986457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid metabolism and renal protection by chronic cicletanine treatment in Dahl salt-sensitive rats with salt-induced hypertension.
    Uehara Y; Hirawa N; Kawabata Y; Akie Y; Ichikawa A; Funahashi N; Goto A; Omata M
    Blood Press; 1997 May; 6(3):180-7. PubMed ID: 9181257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antihypertensive agent cicletanine reverses vascular hyperreactivity to noradrenaline and cardiac hypertrophy in DOCA-salt rats.
    Castro A; Parra L; Alsasua A; Fuentes JA
    Arch Int Pharmacodyn Ther; 1990; 307():109-18. PubMed ID: 2151359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular actions of cicletanine.
    Bukoski RD; Wagman DW; de Wan P; Xue H
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():45-50. PubMed ID: 2514668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible radical scavenging properties of cicletanine and renal protection in Dahl salt sensitive rats.
    Uehara Y; Kawabata Y; Hirawa N; Takada S; Nagata T; Numabe A; Iwai J; Sugimoto T
    Am J Hypertens; 1993 Jun; 6(6 Pt 1):463-72. PubMed ID: 8343228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive profile of cicletanine, a furopyridine derivative: comparison with captopril, indapamide and prazosin.
    Malherbe E; Auguet M; Delaflotte S; Le Hégarat M; Baranes J; Clostre F; Braquet P
    Pharmacol Res Commun; 1988 Sep; 20 Suppl 3():121-33. PubMed ID: 2976170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.
    Fedorova OV; Talan MI; Agalakova NI; Droy-Lefaix MT; Lakatta EG; Bagrov AY
    Hypertension; 2003 Mar; 41(3):505-11. PubMed ID: 12623951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro effects of cicletanine in spontaneously hypertensive rats.
    Auguet M; Guillon JM; Delaflotte S; Le Hegarat M; Pirotzky E; Clostre F; Braquet P
    Drugs Exp Clin Res; 1988; 14(2-3):89-95. PubMed ID: 3416727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cicletanine avoids the proliferation of vascular smooth muscle in the spontaneously hypertensive rat].
    Bukoski RD
    Arch Mal Coeur Vaiss; 1990 Jul; 83(8):1313-6. PubMed ID: 2124474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide, peroxynitrite and cGMP in atherosclerosis-induced hypertension in rabbits: beneficial effects of cicletanine.
    Szilvássy Z; Csont T; Páli T; Droy-Lefaix MT; Ferdinandy P
    J Vasc Res; 2001; 38(1):39-46. PubMed ID: 11173993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of cicletanine on vascular smooth muscle cell proliferation.
    Sato M; Abe K; Yasujima M; Omata K; Fang S; Tsunoda K; Kudo K; Takeuchi K; Hagino T; Kanazawa M
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():63-6. PubMed ID: 2514671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the mechanism of action of the antihypertensive agent cicletanine.
    Castro A; Parra L; Fuentes JA
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():51-4. PubMed ID: 2514669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cicletanine on histamine-induced contractions of isolated rabbit mesenteric arteries.
    Ebeigbe AB; Cabanie M; Godfraind T
    Fundam Clin Pharmacol; 1989; 3(3):223-35. PubMed ID: 2767605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cicletanine and eicosanoids in cultured vascular smooth muscle cells.
    Dorian B; Daret D; Braquet P; Larrue J
    Drugs Exp Clin Res; 1988; 14(2-3):117-22. PubMed ID: 3138094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy.
    Hayakawa H; Coffee K; Raij L
    Circulation; 1997 Oct; 96(7):2407-13. PubMed ID: 9337217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of acute and subchronic treatment with cicletanine on DOCA-salt hypertension in the rat.
    Fuentes JA; Castro A; Alsasua A
    Am J Hypertens; 1989 Sep; 2(9):718-20. PubMed ID: 2803677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifications of the arterial mechanical properties of normotensive and hypertensive rats without arterial pressure changes.
    Levy BI; Curmi P; Poitevin P; Safar ME
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):253-9. PubMed ID: 2476599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General pharmacology of cicletanine.
    Clostre F; Etienne A
    Drugs Exp Clin Res; 1988; 14(2-3):73-82. PubMed ID: 3416726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.